AG2R LA Mondiale Gestion D Actifs Invests $1.14 Million in Labcorp Holdings Inc. $LH

Key Points

• AG2R LA Mondiale Gestion D Actifs has acquired a new position in Labcorp Holdings Inc., purchasing 4,592 shares valued at approximately $1,143,000 during the 1st quarter.
• Insider transactions included Director Dwight Gary Gilliland selling 2,000 shares and CEO Adam H. Schechter selling 5,643 shares, reflecting a decrease in their ownership stakes.
• Labcorp recently announced a $0.72 quarterly dividend with an annual yield of 1.0%, alongside promising earnings results that exceeded analysts' expectations.

AG2R LA Mondiale Gestion D Actifs acquired a new stake in Labcorp Holdings Inc. (NYSE:LH - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 4,592 shares of the medical research company's stock, valued at approximately $1,143,000.

Other large investors have also modified their holdings of the company. Voya Investment Management LLC raised its stake in shares of Labcorp by 111.2% during the first quarter. Voya Investment Management LLC now owns 52,630 shares of the medical research company's stock worth $12,249,000 after purchasing an additional 27,708 shares during the last quarter. eCIO Inc. purchased a new stake in shares of Labcorp during the first quarter worth approximately $94,000. Strs Ohio purchased a new stake in shares of Labcorp during the first quarter worth approximately $23,639,000. IFM Investors Pty Ltd raised its stake in shares of Labcorp by 2.6% during the first quarter. IFM Investors Pty Ltd now owns 15,859 shares of the medical research company's stock worth $3,691,000 after purchasing an additional 404 shares during the last quarter. Finally, Belpointe Asset Management LLC raised its stake in shares of Labcorp by 7.4% during the first quarter. Belpointe Asset Management LLC now owns 1,725 shares of the medical research company's stock worth $402,000 after purchasing an additional 119 shares during the last quarter. 95.94% of the stock is owned by institutional investors and hedge funds.

Labcorp Price Performance

Shares of LH traded down $0.10 during trading hours on Friday, reaching $277.05. 116,648 shares of the company traded hands, compared to its average volume of 685,044. The company has a quick ratio of 1.32, a current ratio of 1.50 and a debt-to-equity ratio of 0.61. The stock has a market capitalization of $23.02 billion, a PE ratio of 30.58, a price-to-earnings-growth ratio of 1.77 and a beta of 0.85. Labcorp Holdings Inc. has a fifty-two week low of $209.38 and a fifty-two week high of $283.47. The stock has a fifty day simple moving average of $267.34 and a 200 day simple moving average of $251.79.

Labcorp (NYSE:LH - Get Free Report) last posted its quarterly earnings data on Thursday, July 24th. The medical research company reported $4.35 EPS for the quarter, beating analysts' consensus estimates of $4.14 by $0.21. The business had revenue of $3.53 billion for the quarter, compared to analyst estimates of $3.49 billion. Labcorp had a return on equity of 15.45% and a net margin of 5.66%.The business's revenue for the quarter was up 9.6% compared to the same quarter last year. During the same quarter last year, the company earned $3.94 earnings per share. Labcorp has set its FY 2025 guidance at 16.050-16.500 EPS. As a group, research analysts predict that Labcorp Holdings Inc. will post 16.01 EPS for the current fiscal year.

Labcorp Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, September 11th. Shareholders of record on Thursday, August 28th were paid a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date of this dividend was Thursday, August 28th. Labcorp's dividend payout ratio (DPR) is presently 31.79%.

Insiders Place Their Bets

In other Labcorp news, Director Dwight Gary Gilliland sold 2,000 shares of the firm's stock in a transaction dated Wednesday, July 30th. The stock was sold at an average price of $264.95, for a total value of $529,900.00. Following the sale, the director directly owned 6,656 shares of the company's stock, valued at approximately $1,763,507.20. This trade represents a 23.11% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Kerrii B. Anderson sold 3,500 shares of the firm's stock in a transaction dated Thursday, July 24th. The stock was sold at an average price of $280.00, for a total value of $980,000.00. Following the completion of the sale, the director directly owned 8,666 shares in the company, valued at approximately $2,426,480. The trade was a 28.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 15,546 shares of company stock valued at $4,207,192 in the last quarter. Corporate insiders own 0.84% of the company's stock.

Analyst Ratings Changes

LH has been the subject of several analyst reports. Barclays restated a "cautious" rating on shares of Labcorp in a research note on Wednesday, June 25th. Evercore ISI upped their price target on Labcorp from $285.00 to $300.00 and gave the stock an "outperform" rating in a research note on Friday, July 25th. Morgan Stanley increased their price objective on Labcorp from $283.00 to $306.00 and gave the stock an "overweight" rating in a research report on Friday, July 25th. Robert W. Baird set a $311.00 price objective on Labcorp in a research report on Monday, August 25th. Finally, UBS Group increased their price objective on Labcorp from $282.00 to $305.00 and gave the stock a "buy" rating in a research report on Friday, July 25th. Nine analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $290.33.

About Labcorp

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.